BlackRock Group’s Theravance Biopharma TBPH Stock Holding History

BlackRock Group’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.22M	Buy	38,390 +5,084	+15%	+$158K	﹤0.01%	2033
2016 Q3	$1.21M	Buy	33,306 +1,665	+5%	+$46.4K	﹤0.01%	1932
2016 Q2	$718K	Sell	31,641 -160	-0.5%	-$3.46K	﹤0.01%	2120
2016 Q1	$598K	Buy	31,801 +3,604	+13%	+$59K	﹤0.01%	2160
2015 Q4	$463K	Sell	28,197 -213	-0.7%	-$3.38K	﹤0.01%	2229
2015 Q3	$313K	Buy	28,410 +1,100	+4%	+$14K	﹤0.01%	2387
2015 Q2	$355K	Buy	27,310 +1,325	+5%	+$20.5K	﹤0.01%	2386
2015 Q1	$451K	Buy	25,985 +930	+4%	+$17K	﹤0.01%	2237
2014 Q4	$374K	Buy	25,055 +12,582	+101%	+$219K	﹤0.01%	2333
2014 Q3	$287K	Buy	12,473 +2,990	+32%	+$86.7K	﹤0.01%	2353
2014 Q2	$302K	Buy	+9,483	New	+$285K	﹤0.01%	2355

Other funds holding TBPH

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Group's TBPH Position: Q4 2016 in Review

BlackRock Group increased its Theravance Biopharma (TBPH) stake by 15% in Q4 2016, buying an estimated $158K and bringing the position to 38,390 shares worth $1.22M. The position accounts for ﹤0.01% of the portfolio, ranked #2033.

BlackRock Group first reported a position in TBPH in Q2 2014 and has held it in 11 quarters since. 98 funds tracked by Wall St. Rank hold TBPH as of Q4 2016.

BlackRock Group held 38,390 shares of Theravance Biopharma worth $1.22M as of Q4 2016.
BlackRock Group bought 5,084 Theravance Biopharma shares in Q4 2016, an estimated $158K.
Theravance Biopharma made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2033 holding.
BlackRock Group first reported a position in Theravance Biopharma in Q2 2014 and has held it in 11 quarters since.
98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.